Pharmacokinetics of Levodopa after Subcutaneous bolus delivery of foslevodopa/foscarbidopa
Objective: To characterize the pharmacokinetics (PK) of levodopa (LD) after bolus delivery of foslevodopa/foscarbidopa Background: Foslevodopa/foscarbidopa is a soluble formulation of LD/CD prodrugs delivered as…Longitudinal Changes in Quality of Life After Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
Objective: To clarify longitudinal changes in QOL in PD after STN-DBS. Background: While it is well known that motor complications are dramatically improved after subthalamic…Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson’s Disease in the End-of-Life Period
Objective: To determine whether antipsychotic prescriptions differ between community-dwelling and nursing home residents with PD in the last 6 months of life. Background: Most antipsychotics…Deciphering the Role of Auranofin-Loaded Nanoparticles Against Rotenone Model of Parkinson’s Disease: Via GSK-3β/ Nrf2/HO-1 Signaling Pathways
Objective: To investigate the neuroprotective effect of AUF-loaded nanoparticles in animal models of Parkinson's disease by modulating GSK-3β/ Nrf2/HO-1 Signaling Pathways. Background: Parkinson's disease (PD) is…Genetic signatures stratify PwP into three subgroups with differing responses in two disease-modifying Phase 3 trials and indicate multiple disease biology pathways to Parkinson’s Disease
Objective: To evaluate if 3 newfound genetic subgroups represent differing aspects of disease biology in PD by determining if subgroup participants have differing responses to…Safety and Tolerability of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study
Objective: To report the safety and tolerability of bemdaneprocel in participants with Parkinson’s disease (PD) up to 24 months post transplantation. Background: Bemdaneprocel is an…Resting-State Network Alterations in Patients with Isolated REM Sleep Behavior Disorder and their Association with Clinical Symptoms
Objective: To characterize brain functional connectivity (FC) in patients with isolated REM sleep behavior disorder (iRBD) and its associations with clinical features. Background: Patients with…Decrease in Walking Ability with Increased Functional Connectivity between Multiple Brain Areas in Parkinson’s Disease
Objective: To compare the functional connectivity of PFC, PMC, and PSC regions during walking between individuals with Parkinson's disease and healthy controls. Background: Gait disturbances…The 2-Minute Walking Test Predicts Aerobic Fitness, Motor Function, and Brain Health in Parkinson’s Disease
Objective: To determine the association of performance on the 2-Minute Walking Test (2MWT) with aerobic fitness, motor and cognitive function, and brain health in mild…Transcranial Sonography of the Substantia Nigra and Vagus Nerve Ultrasonography as Complementary Diagnosis for Parkinson’s Disease.
Objective: We aim to investigate the relationship between sonographic abnormalities of the substantia nigra, vagus nerve cross-sectional area and clinical features of PD in different…
- « Previous Page
- 1
- …
- 178
- 179
- 180
- 181
- 182
- …
- 436
- Next Page »